- 5.6 million in cash - 200k coming in from directors on May 2nd - around 4 million dollars in R&D after June 30th to be received this year
They have 10 million in cash available. Not one biotech under a 50 million market cap has the amount of cash we have or the drug reach potential that NYR has and NYR is trading at a 8 million dollar EV when comparable peers targeting similar health conditions with less cash are all around 70 million dollar EV companies when they passed their pre clinical trials. Hence why NYR is heavily undervalued
